Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (440,000)	$ (615,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	61,000	61,000
Amortization of debt issuance costs	82,000	98,000
Allowance for doubtful accounts	(2,000)	3,000
Provision for slow moving and obsolete inventory	63,000	14,000
Share-based payment expense	4,000	8,000
Director fee paid with restricted stock	5,000	3,000
Changes in:
Accounts receivable	(38,000)	(202,000)
Inventory	66,000	209,000
Prepaid expenses and other current assets	11,000	51,000
Accounts payable	247,000	85,000
Accrued expenses and other current liabilities	78,000	114,000
Wages payable	(142,000)	0
Net cash used in operating activities	(5,000)	(171,000)
Cash flows from investing activities:
Patent application costs	0	(21,000)
Net cash used in investing activities	0	(21,000)
Cash flows from financing activities:
Proceeds from debt financing	62,000	150,000
Payments on debt financing	(85,000)	(84,000)
Proceeds from lines of credit	2,876,000	3,194,000
Payments on lines of credit	(2,946,000)	(3,045,000)
Net cash (used in) / provided by financing activities	(93,000)	215,000
Net change in cash and cash equivalents	(98,000)	23,000
Cash and cash equivalents - beginning of period	113,000	36,000
Cash and cash equivalents - end of period	15,000	59,000
Supplemental disclosures of cash flow information
Consulting expense prepaid with restricted stock	0	24,000
Debt issuance cost paid with restricted stock	14,000	18,000
Director Fee paid with restricted stock	5,000	3,000
Patent application costs	0	21,000
Cash paid during period for interest	117,000	118,000
Cash paid during period for taxes	$ 2,000	$ 2,000